 |
|
Is There Any Hope for Vitamin E?
B. Greg Brown, MD, PhD;
John Crowley, PhD
JAMA. 2005;293:1387-1390.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
During the past 15 years, epidemiological,1-2 basic biological,3-5 and experimental studies on atherosclerosis have supported the hypothesis that antioxidants protect against atherosclerosis6-8 by limiting low-density lipoprotein oxidation in the arterial wall. This mechanism inhibits the pathological accumulation of cholesteryl ester in plaque via the macrophage scavenger receptor, a process that can cause plaque rupture and cardiovascular events.9-10 Similarly, biological mechanisms have been identified in carcinogenesis that may be blocked by antioxidants.11-14 In the past decade, a number of prospective, randomized, placebo-controlled, 3- to 6-year clinical trials have been published, testing the effect of vitamin E and other antioxidant vitamins or their combinations on clinical manifestations of cardiovascular disease and cancer.15-21 These trials have surprisingly yet consistently shown that commonly used antioxidant vitamin regimens (vitamins E, C, beta carotene, or a combination) do not significantly reduce overall cardiovascular events or cancer.
Why not? . . . [Full Text of this Article]
Author Affiliations: Department of Medicine, Cardiology Division, University of Washington School of Medicine, Seattle (Dr Brown); Department of Cancer Research and Biostatistics, Fred Hutchinson Cancer Research Center; and Department of Biostatistics, University of Washington School of Public Health and Community Medicine, Seattle (Dr Crowley).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Effects of Long-term Vitamin E Supplementation on Cardiovascular Events and Cancer: A Randomized Controlled Trial
The HOPE and HOPE-TOO Trial Investigators
JAMA. 2005;293(11):1338-1347.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Antioxidant treatment for heart failure: friend or foe?
Thomson et al.
QJM 2009;102:305-310.
ABSTRACT
| FULL TEXT
Assessing Toxicity in Cancer Chemoprevention Trials: The Other Side of the Coin
Goodman
Cancer Prevention Research 2008;1:499-502.
FULL TEXT
Correction of HDL Dysfunction in Individuals With Diabetes and the Haptoglobin 2-2 Genotype
Asleh et al.
Diabetes 2008;57:2794-2800.
ABSTRACT
| FULL TEXT
Dual Therapy With Statins and Antioxidants Is Superior to Statins Alone in Decreasing the Risk of Cardiovascular Disease in a Subgroup of Middle-Aged Individuals With Both Diabetes Mellitus and the Haptoglobin 2-2 Genotype
Blum et al.
Arterioscler. Thromb. Vasc. Bio. 2008;28:e18-e20.
FULL TEXT
Vitamin E Supplementation Reduces Cardiovascular Events in a Subgroup of Middle-Aged Individuals With Both Type 2 Diabetes Mellitus and the Haptoglobin 2-2 Genotype: A Prospective Double-Blinded Clinical Trial
Milman et al.
Arterioscler. Thromb. Vasc. Bio. 2008;28:341-347.
ABSTRACT
| FULL TEXT
Mortality in Randomized Trials of Antioxidant Supplements for Primary and Secondary Prevention: Systematic Review and Meta-analysis
Bjelakovic et al.
JAMA 2007;297:842-857.
ABSTRACT
| FULL TEXT
Haptoglobin Genotype Determines Myocardial Infarct Size in Diabetic Mice
Blum et al.
J Am Coll Cardiol 2007;49:82-87.
ABSTRACT
| FULL TEXT
Clinical trials update from the American College of Cardiology meeting: CARE-HF and the Remission of Heart Failure, Women's Health Study, TNT, COMPASS-HF, VERITAS, CANPAP, PEECH and PREMIER
Cleland et al.
Eur J Heart Fail 2005;7:931-936.
ABSTRACT
| FULL TEXT
Vitamin E Not Helpful Against Heart Disease and Cancer
JWatch Emergency Med. 2005;2005:4-4.
FULL TEXT
Mild Cognitive Impairment -- No Benefit from Vitamin E, Little from Donepezil
Blacker
NEJM 2005;352:2439-2441.
FULL TEXT
From the Library
Br J Ophthalmol 2005;89:788-788.
FULL TEXT
It Looks HOPEless for Vitamin E
Journal Watch Cardiology 2005;2005:2-2.
FULL TEXT
|
